medigraphic.com
ISSN 2078-7170 (Digital)

2016, Número 2

<< Anterior Siguiente >>

CorSalud 2016; 8 (2)


Nefropatía inducida por contraste

García HRA, Hernández NM, Aroche AR, Obregón SÁG

Idioma: Español
Referencias bibliográficas: 56
Paginas: 117-124
Archivo PDF: 208.07 Kb.


RESUMEN

La nefropatía inducida por contraste representa un importante efecto adverso derivado de la administración de medios de contraste. Los factores favorecedores han sido ampliamente descritos entre los que destacan la diabetes mellitus y la enfermedad renal preexistente. La fisiopatología constituye un proceso complejo en el que la hipoxia medular constituye el elemento detonante. Las medidas preventivas mayormente recomendadas son la hidratación previa y el empleo de contraste de baja osmolalidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ellis JH, Cohan RH. Reducing the risk of contrastinduced nephropathy: A perspective on the controversies. AJR Am J Roentgenol. 2009;192:1544-9.

  2. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: Clinical landscape. Kidney Int. 2006;69: S3-S7.

  3. Fernández-Cimadevilla OC, Barriales-Alvarez V, Lozano-Martínez Luengas I. Nefropatía inducida por contraste. Med Clin (Barc). 2011;137:84-90.

  4. Mehran R, Nikolsky E. Contraste-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int. 2006;69:S11-5.

  5. González Reinoso R, Roldós Cuza E, Zabala García A. Complicaciones médicas y vasculares. En: Obregón Santos AG, Conde Cerdeira H, Aroche Aportela R, eds. Manual de Cardiología Intervencionista. La Habana: CIMEQ; 2010. p. 232-52.

  6. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings? J Nephrol. 2009;22:333-51.

  7. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv. 2001;53:341-5.

  8. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150:170-7.

  9. Fernández de Bobadilla J, López-Sendón J. Enfermedad renal: implicaciones terapéuticas en insuficiencia cardíaca y cardiopatía isquémica. Med Clin (Barc). 2009;132(Supl. 1):48-54.

  10. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol. 2004;44:1393-9.

  11. Martínez-Castelao A, Górriz JL, Bover J, Segura de la Morena J, Cebollada J, Escalada J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Aten Primaria. 2014;46:501-19.

  12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.

  13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.

  14. Álcazar R, Egocheaga MI, Orte L, Lobos JM, González Parra E, Álvarez Guisasola F, et al. Documento de consenso sobre SEN-semFYC sobre la enfermedad renal crónica. Nefrología. 2008;28: 273-82.

  15. Anónimo. Management of progression and complications of CKD. Kidney Int Suppl. 2013;3: 73-90.

  16. Pallone TL, Zhang Z, Rhinehart K. Physiology of the renal medullary microcirculation. Am J Physiol Renal Physiol. 2003;284:253-66.

  17. Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol. 2008;3:288-96.

  18. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005;68:14-22.

  19. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007- 15.

  20. Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Prophylaxis strategies for contrastinduced nephropathy. JAMA. 2006;295:2765-79.

  21. Sendeski M, Patzak A, Persson PB. Constriction of the vasa recta, the vessels supplying the area at risk for acute kidney injury, by four different iodinated contrast media, evaluating ionic, nonionic, monomeric and dimeric agents. Invest Radiol. 2010;45:453-7.

  22. Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology. 2009; 251:697-704.

  23. Cao C, Edwards A, Sendeski M, Lee-Kwon W, Cui L, Cai CY, et al. Intrinsic nitric oxide and superoxide production regulates descending vasa recta contraction. Am J Physiol Renal Physiol. 2010; 299:F1056-64.

  24. Fanning NF, Manning BJ, Buckley J, Redmond HP. Iodinated contrast media induce neutrophil apoptosis through a mitochondrial and caspase mediated pathway. Br J Radiol. 2002;75:861-73.

  25. Sendeski MM. The pathophysiology of renal tissue damage by iodinated contrast media. Clin Exp Pharmacol Physiol. 2011;38:292-9.

  26. Popma JJ. Coronariografía. En: Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E, eds. Braunwald Tratado de Cardiología: Texto de Medicina Cardiovascular. 9na ed. Barcelona: Elsevier Espa- ña, SL; 2012. p. 411-36.

  27. Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol. 2010;6:679-88.

  28. Lancelot E, Idée JM, Laclédère C, Santus R, Corot C. Effects of two dimeric iodinated contrast media on renal medullary blood perfusion and oxygenation in dogs. Invest Radiol. 2002;37:368-75.

  29. Ueda J, Furukawa T, Higashino K, Takahashi S, Araki Y, Kubo K, et al. Urine viscosity after injections of iotrolan or iomeprol. Acta Radiol. 1997;38:1079-82.

  30. Seeliger E, Flemming B, Wronski T, Ladwig M, Arakelyan K, Godes M, et al. Viscosity of contrast media perturbs renal hemodynamics. J Am Soc Nephrol. 2007:18:2912-20.

  31. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98:27K-36K.

  32. Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, et al. Outcomes of optimal or "stent-like" balloon angioplasty in acute myocardial infarction: the CADILLAC trial. J Am Coll Cardiol. 2003;42:971-7.

  33. Bouzas-Mosquera A, Vázquez-Rodríguez JM, Calviño-Santos R, Peteiro-Vázquez J, Flores-Ríos X, Marzoa-Rivas R, et al. Nefropatía inducida por contraste y fracaso renal agudo tras cateterismo cardíaco urgente: incidencia, factores de riesgo y pronóstico. Rev Esp Cardiol. 2007;60:1026-34.

  34. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780-5.

  35. Aguiar-Souto P, Ferrante G, Del Furia F, Barlis P, Khurana R, Di Mario C. Frequency and predictors of contrast-induced nephropathy after angioplasty for chronic total occlusions. Int J Cardiol. 2010;139:68-74.

  36. Weisbord SD, Palevsky PM. Strategies for the prevention of contrast-induced acute kidney injury. Curr Opin Nephrol Hypertens. 2010;19:539-49.

  37. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-82.

  38. Sjödin K, Nilsson E, Hallberg A, Tunek A. Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol. 1989;38:3981-5.

  39. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1584-92.

  40. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21:2527- 41

  41. Seeliger E, Wronski T, Ladwig M, Dobrowolski L, Vogel T, Godes M, et al. The renin-angiotensin system and the third mechanism of renal blood flow autoregulation. Am J Physiol Renal Physiol. 2009;296:F1334-45.

  42. Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr. 2008;120:742-8.

  43. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124:1260-9.

  44. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Sodium bicarbonate versus saline for the prevention of contrastinduced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599-604.

  45. Seeliger E, Ladwig M, Sargsyan L, Cantow K, Persson PB, Flemming B. Proof of principle: hydration by low-osmolar mannitol-glucose solution alleviates undesirable renal effects of an isoosmolar contrast medium in rats. Invest Radiol. 2012;47:240-6.

  46. Liss P, Nygren A, Ulfendahl HR, Erikson U. Effect of furosemide or mannitol before injection of a non-ionic contrast medium on intrarenal oxygen tension. Adv Exp Med Biol. 1999;471:353-9.

  47. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis with Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5:90- 7.

  48. Revilla Martí P, Linares Vicente JA, Lukic A, Artero Bello P, Bascompte Claret R, Matajira Chia T, et al. Profilaxis de la nefropatía inducida por contraste en pacientes de alto riesgo con síndrome coronario agudo sin elevación del segmento ST. CorSalud [Internet]. 2012 [citado 3 Sept 2015];4:151-6. Disponible en: http://www.corsalud.sld.cu/sumario/2012/v4n3a1 2/nefropatia.html

  49. Tasanarong A, Piyayotai D, Thitiarchakul S. Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study. J Med Assoc Thai. 2009;92: 1273-81.

  50. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, et al. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study - A prospective randomized controlled trial. Am Heart J. 2009;157: 576-83.

  51. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101:279-85.

  52. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010;105:288-92.

  53. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61:711-4.

  54. Waaler A, Svaland M, Fauchald P, Jakobsen JA, Kolmannskog F, Berg KJ, et al. Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure. Nephron. 1990;56:81-5.

  55. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006;119:155-62.

  56. Lee PT, Chou KJ, Liu CP, Mar GY, Chen CL, Hsu CY, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol. 2007;50:1015-20.




2020     |     www.medigraphic.com